Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
AN2 Therapeutics Inc
ANTXCurrent price
1.09 USD
-0.02 USD (-1.80%)
Last closed
1.1 USD
Company
www.an2therapeutics.com
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
32 826 640 USD
Yield for 12 month
-92.73 %
1Y
3Y
5Y
10Y
15Y
ANTX
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. Address: 1800 El Camino Real, Menlo Park, CA, United States, 94027
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.33 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
+80 000 USD
Current Year
–
Last Year
-77 000 USD
Current Quarter
–
Last Quarter
+40 000 USD
Key Figures ANTX
1 year
3 years
5 years
10 years
EBITDA
–
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-42.89 %
PEG Ratio
–
Return On Equity TTM
-69.48 %
Wall Street Target Price
10.33 USD
Revenue TTM
–
Book Value
3.3 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-2.18 USD
Diluted Eps TTM
-2.18 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ANTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ANTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ANTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-2.1095
Price Book MRQ
0.3322
Financials ANTX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ANTX
For 52 weeks
0.87 USD
22.22 USD
50 Day MA
1.06 USD
Shares Short Prior Month
188 480
200 Day MA
3.09 USD
Short Ratio
0.84
Shares Short
139 119
Short Percent
0.72 %
BeatStart